Loading...
Docoh

Redhill Biopharma (RDHL)

Utility
All-in-one Fixed-dose Combination for Treating Helicobacter Pylori Infection
3 Mar 22
Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein.
Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
Filed: 20 Aug 21
Utility
Sphingosine Kinase 2 Inhibitor for Treating Coronavirus Infection
3 Feb 22
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Dror Ben-Asher, Reza Fathi
Filed: 15 Oct 21
Utility
Triple Antibiotic Fixed-dose Combination Products, Dosing Regimen, Methods, and Kits for Treating Pulmonary Non-tuberculosis Mycobacterial Infections
30 Dec 21
A fixed-dose combination drug product formulated for oral delivery comprises a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin.
Reza Fathi, Gilead Raday, Patricia Anderson, Elliot Offman
Filed: 30 Jun 21
Utility
Inhibitor of Sphingosine Kinase 2 for Treating Ebola
2 Dec 21
Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed.
Reza Fathi, Dror Ben-Asher, Guy Goldberg
Filed: 13 Aug 21
Utility
Method for Eradicating Helicobacter Pylori Infection In Patients Regardless of Body Mass Index
11 Nov 21
A method of treating patients who are positive for Helicobacter pylori infection comprises determining that a first patient who is positive for Helicobacter pylori infection has a body mass index corresponding to normal weight or overweight; determining that a second patient who is positive for Helicobacter pylori infection has a body mass index corresponding to obese or extremely obese; and administering to both the first patient and the second patient, for 14 days, a rifabutin-based triple therapy consisting essentially of rifabutin, amoxicillin and omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein, after treatment is complete, there is no substantial difference in the efficacy of the treatment when the treatment is administered to the first patient or the second patient.
Reza Fathi, Kely Lee Sheldon
Filed: 7 May 20
Utility
Sphingosine Kinase 2 Inhibitor for Treating Coronavirus Infection
21 Oct 21
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Dror Ben-Asher, Reza Fathi
Filed: 30 Jun 21
Utility
Rifabutin-based compositions and methods for treating
5 Oct 21
Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein.
Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
Filed: 18 Jul 19
Utility
Serine Protease Inhibitor for Treating Coronavirus Infection
30 Sep 21
The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Dror Ben-Asher, Reza Fathi
Filed: 10 Jun 21
Utility
Compositions for treating ebola virus infection
17 Aug 21
Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed.
Reza Fathi, Dror Ben-Asher, Guy Goldberg
Filed: 24 Jan 20
Utility
Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine
17 Aug 21
Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection.
Thomas Julius Borody, Patrick Gosselin
Filed: 12 Mar 20
Utility
Formulations and methods of manufacturing formulations for use in colonic evacuation
13 Jul 21
Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.
Reza Fathi, Patrick Laughlin Mclean
Filed: 25 Oct 19
Utility
Sphingosine kinase 2 inhibitor for treating coronavirus infection
6 Jul 21
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Dror Ben-Asher, Reza Fathi
Filed: 8 Mar 21
Utility
Serine protease inhibitor for treating coronavirus infection
29 Jun 21
The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Dror Ben-Asher, Reza Fathi
Filed: 8 Mar 21
Utility
Combination Compositions for Treatment of Cancer
6 May 21
Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound.
Reza Fathi, Dror Ben-Asher, Danielle Abramson
Filed: 12 Jan 21
Utility
Method for treating cancer with combination therapy
16 Mar 21
Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound.
Reza Fathi, Dror Ben-Asher, Danielle Abramson
Filed: 17 Sep 19
Utility
Methods for treating helicobacter pylori infection
26 Jan 21
Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein.
Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
Filed: 13 Feb 19
Utility
Bimodal Release Ondansetron Tablets and Methods of Treating Nausea and Vomiting
21 Oct 20
A solid oral dosage form includes a core comprising a non-ionic polymer matrix, a first amount of a first antiemetic drug or a pharmaceutically acceptable salt thereof dispersed within the matrix, and a salt dispersed within the matrix; a first seal coat of a non-ionic polymer matrix surrounding the core; and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of a second antiemetic drug or a pharmaceutically acceptable salt thereof dispersed therein, wherein the drug layer is sufficiently designed to release the second amount of the antiemetic drug over a period of at least 1 hour, wherein the solid oral dosage form is sufficiently designed to release the first amount of the first antiemetic drug and the second amount of the second antiemetic drug over a minimum period of 16 hours.
Reza Fathi, Gilead Raday
Filed: 30 Jun 20
Utility
Method for treating crohn's disease using triple antimicrobial all-in-one formulation
7 Sep 20
Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection.
Thomas Julius Borody, Patrick Gosselin
Filed: 27 Aug 19
Utility
Methods for Treating Diarrhea Predominant Irritable Bowel Syndrome
12 Aug 20
A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.
Reza Fathi, Gilead Raday, Guy Goldberg
Filed: 28 Apr 20
Utility
Formulations and Methods of Manufacturing Formulations for Use In Colonic Evacuation
15 Jul 20
Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.
Reza Fathi, Patrick Laughlin Mclean
Filed: 24 Oct 19
Patents are sorted by USPTO publication date, most recent first